Related references
Note: Only part of the references are listed.Progesterone receptor modulators and the endometrium: changes and consequences
Frances McFarland Horne et al.
HUMAN REPRODUCTION UPDATE (2007)
Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: A prospective, randomized, placebo-controlled trial
Nathalie Chabbert-Buffet et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata
A. R. W. Williams et al.
HUMAN REPRODUCTION (2007)
Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia
George L. Mutter et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2007)
Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas
SH Eisinger et al.
JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY (2005)
Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications
N Chabbert-Buffet et al.
HUMAN REPRODUCTION UPDATE (2005)
Discovery, chemistry, and reproductive pharmacology of asoprisnil and related 11β-benzaldoxime substituted selective progesterone receptor modulators (SPRMs)
G Schubert et al.
SEMINARS IN REPRODUCTIVE MEDICINE (2005)
Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor
N Narvekar et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Development of the selective progesterone receptor modulator CDB-2914 for clinical indications
DL Blithe et al.
STEROIDS (2003)
Mifepristone: a novel estrogen-free daily contraceptive pill
DT Baird et al.
STEROIDS (2003)
Effect of long-term treatment with low-dose mifepristone on the endometrium
DT Baird et al.
HUMAN REPRODUCTION (2003)
Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: A double-blind randomized control trial of 2 and 5 mg per day for 120 days
A Brown et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Progesterone antagonists increase androgen receptor expression in the rhesus macaque and human endometrium
OD Slayden et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study
A Zeleniuch-Jacquotte et al.
BRITISH JOURNAL OF CANCER (2001)
RU486-induced growth inhibition of human endometrial cells
AA Murphy et al.
FERTILITY AND STERILITY (2000)
Share Paper
